KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Capital Leases (2020 - 2022)

Historic Capital Leases for Ginkgo Bioworks Holdings (DNA) over the last 3 years, with Q3 2022 value amounting to $59.8 million.

  • Ginkgo Bioworks Holdings' Capital Leases rose 26785.1% to $59.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $59.8 million, marking a year-over-year increase of 26785.1%. This contributed to the annual value of $22.3 million for FY2021, which is 3490.13% up from last year.
  • Per Ginkgo Bioworks Holdings' latest filing, its Capital Leases stood at $59.8 million for Q3 2022, which was up 26785.1% from $51.5 million recorded in Q2 2022.
  • Over the past 5 years, Ginkgo Bioworks Holdings' Capital Leases peaked at $59.8 million during Q3 2022, and registered a low of $16.3 million during Q3 2021.
  • Its 3-year average for Capital Leases is $32.3 million, with a median of $24.8 million in 2021.
  • Its Capital Leases has fluctuated over the past 5 years, first skyrocketed by 3490.13% in 2021, then soared by 26785.1% in 2022.
  • Ginkgo Bioworks Holdings' Capital Leases (Quarter) stood at $16.5 million in 2020, then surged by 34.9% to $22.3 million in 2021, then soared by 168.55% to $59.8 million in 2022.
  • Its Capital Leases stands at $59.8 million for Q3 2022, versus $51.5 million for Q2 2022 and $27.3 million for Q1 2022.